Muhammad Aqib Faizan: The Role of Novel Anticoagulants Factor XI/XIa Inhibitors in the Atrial Fibrillation Population
Muhammad Aqib Faizan, Clinical Intern at District Headquarter Hospital, MTI, DIKhan, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”New study
I had the privilege of leading this study regarding the role of novel anticoagulants FactorXI/XIa inhibitors in atrial fibrillation population (high-thromboembolic-risk patients (mean CHA2DS2-VASc scores 3.9-5.0).
The findings offer a compelling trade-off.
- Significantly lower risk of bleeding across all doses
- Fourfold rise in ischemic stroke
- No significant difference in cardiovascular death, all-cause mortality, or major adverse events indicates general tolerance and neutrality in survival outcomes.
This profile may offer a lifeline for high-risk patients-those in whom bleeding concerns limit traditional anticoagulation.
But the fourfold increase in ischemic stroke is a critical signal.
Proud of what this team accomplished. Huge thanks to Tooba Rehman, Zeyad Kholeif, Fatima Saeed, Jibran Ikram, Alina Tanvir, Carlos Alberto E., Saad Ahmed Waqas, and our mentor, Luis Cerna, whose insights made this happen.”
Title: Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation
Authors: Muhammad Aqib Faizan, Tooba Rehman, Mrunalini Dandamudi, Jaivardhan A. Menon, Victoria Zecchin Ferrara, Zeyad Kholeif, Alina Tanvir, Fatima Saeed, Jibran Ikram, Moiuz Chaudhri, Carlos Espiche, Main Muhammad Salman Aslam, Zainab Humayun, Ahmad Mustafa Khalid, Saad Ahmad Waqas, Raheel Ahmad, Luis Cerna
Read the Full Article on Clinical Cardiology.
Stay updated with Hemostasis Today.
-
Oct 2, 2026, 16:02Advancing Antithrombotic Stewardship to Optimise Care – American Heart Association
-
Oct 2, 2026, 15:37Pall T. Onundarson: Monitoring Warfarin Beyond Factor VII
-
Oct 2, 2026, 15:26Nicola Carter: World Thrombosis Day Highlights Gender Specific Risks and Prevention
-
Oct 2, 2026, 14:56Wolfgang Miesbach: Direct Comparison Reveals Distinct Mechanisms Among FVIIIa Mimetics
-
Oct 2, 2026, 14:47Strengthening Hemophilia Care Through Advocacy and Partnership – World Federation of Hemophilia
-
Oct 2, 2026, 14:40Maxime Dely: CAR T Cell Therapy Starts With Collection
-
Oct 2, 2026, 14:30Sadashiva Pai: The Molecular Gateway for Sphingosine-1-Phosphate Release
-
Oct 2, 2026, 14:17Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
-
Oct 2, 2026, 14:12Monitoring Iron Deficiency in Glanzmann Thrombasthenia – Glanzmann’s Research Foundation